Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors

Trial Profile

Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs JS 001 (Primary)
  • Indications Cholangiocarcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Nasopharyngeal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shanghai Junshi Biosciences
  • Most Recent Events

    • 06 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
    • 27 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
    • 12 Sep 2017 Enrollment for this study was completed by October 2016, according to results presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top